Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liothyronine + sertraline is a combination of two pharmaceutical drugs used in clinical research for the treatment of major depressive disorder. Liothyronine (triiodothyronine, T3) is a synthetic form of the thyroid hormone that regulates metabolism and has been investigated as an adjunct to antidepressant therapy. Sertraline is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression. The rationale for combining these agents stems from evidence that thyroid hormones may potentiate or accelerate antidepressant effects. Clinical trials have shown mixed results regarding efficacy; some studies report enhanced response and remission rates when liothyronine is added to sertraline in patients with major depressive disorder, while others do not find significant benefit over monotherapy[1][2][5]. The combination appears generally well tolerated without significant increases in adverse effects compared to monotherapy[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liothyronine + sertraline.